Shares in Oxford University spin out Summit Therapeutics have taken a nosedive after the firm’s flagship drug ezutromid failed to hit targets in a mid-stage trial in patients with Duchenne muscular dystrophy (DMD). More: Summit shares plummet on DMD drug
read moreArray will challenge pharma giants Novartis and Roche in its rollout of new cancer drugs Braftovi and Mektovi. More: Ready to challenge Novartis and Roche, Array scores FDA nod for melanoma combo Source: fierce
read moreWomen only hold a quarter of all C-level biopharma jobs, and when they do make it to the top, women are overall paid far less compared to many of their male counterparts. Here, we list the top 5 highest-paid female
read moreBiopharma M&A has picked up this year with deals worth more than $34 billion so far, not counting Takeda’s $62 billion offer for Shire. Now, the much smaller Spectrum Pharmaceuticals—with six marketed drugs and $116 million in 2017 sales—is testing
read moreIt turns out that investor opposition to Takeda’s $62 billion buyout of Shire comes down to blood. Investors are concerned that competition to Shire’s hemophilia drugs for blood disease cut its revenues so much that it will make the deal
read moreTeva’s mega-cost-cutting drive hasn’t been popular with workers or its home country of Israel. Analysts, on the other hand, like what they’ve seen so far from the company’s new C-suite team. More: Less than a year into the job, 'action-oriented'
read more© 1994 - 2026 B.M. Pharmaceuticals